Toxicity assessment of molindone hydrochloride, a dopamine D2/D5 receptor antagonist in juvenile and adult rats

References

• Baldessarini R, Tarazi F. (2001). Drugs and the treatment of psychiatric disorders. In Hardman J, Limbird L, Gilman A, eds. Psychosis and mania. 10th ed. New York: McGraw-Hill, 485–520.
   Google Scholar
• Baldrick P. (2004). Developing drugs for pediatric use: a role for juvenile animal studies? Regul Toxicol Pharmacol 39:381–9.
   PubMed Web of Science ®Google Scholar
• Ben-Jonathan N, Lapensee CR, Lapensee EW. (2008). What can we learn from rodents about prolactin in humans? Endocrine Rev 29:1–41.
   PubMed Web of Science ®Google Scholar
• Callier S, Snapyan M, Le Crom S, et al. (2003). Evolution and cell biology of dopamine receptors in vertebrates. Biol Cell 95:489–502.
   PubMed Web of Science ®Google Scholar
• Carboni L, Negri M, Michielin F, et al. (2012). Slow dissociation of partial agonists from the D2 receptor is linked to reduced prolactin release. Int J Neuropsychopharmacol 15:645–56.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.Gov. (2011). A study to evaluate the efficacy and safety of molindone hydrochloride XR tablets as adjunctive therapy in children with impulsive aggression comorbid with attention-deficit/hyperactivity disorder (ADHD). NCT01364662. [Online]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01364662?term=molindone&rank=3 [updated 22 May 2013; last accessed 18 Nov 2015].
   Google Scholar
• De Waal EJ, Desmidt M, Korte S, et al. (2014). Differential responses to JNJ-37822681, a specific and fast dissociating dopamine D2 receptor antagonist, in cynomolgus monkey and Sprague–Dawley rat general toxicology studies: clinical observations, prolactin levels, mammary histopathology findings and toxicokinetics. J Appl Toxicol 34:974–92.
   PubMed Web of Science ®Google Scholar
• Hall AP, Elcombe CR, Foster JR, et al. (2012). Liver hypertrophy: a review of adaptive (adverse and non-adverse) changes-conclusions from the 3rd International ESTP Expert Workshop. Toxicol Pathol 40:971–94.
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation (ICH). (2008). Dose selection for carcinogenicity studies of pharmaceuticals: S1C(R2). ICH Harmonised Tripartite Guideline.
   Google Scholar
• International Conference on Harmonisation (ICH). (2014). Nonclinical safety testing in support of development of pediatric medicines: S11, Final Concept Paper.
   Google Scholar
• Izumi Y, Watanabe T, Awasaki N, et al. (2009). Collaborative work on evaluation of ovarian toxicity: effects of 2 or 4 weeks repeated dose studies and fertility study of Chlorpromazine hydrochloride in rats. J Toxicol Sci 34:SP167–74.
   Google Scholar
• Krishna G, Ganiger S, Kannan K, et al. (2015). Reversibility of dopamine receptor antagonist-induced hyperprolactinemia and associated histological changes in Tg RasH2 wild-type mice. Reprod Toxicol 58:73–8.
   PubMed Web of Science ®Google Scholar
• Kunimatsu T, Kimura J, Funabashi H, et al. (2010). The antipsychotics haloperidol and chlorpromazine increase bone metabolism and induce osteopenia in female rats. Regul Toxicol Pharmacol 58:360–8.
   PubMed Web of Science ®Google Scholar
• Lucas JN, Rudmann DG, Credille KM, et al. (2007). The rat mammary gland: morphologic changes as an indicator of systemic hormonal perturbations induced by xenobiotics. Toxicol Pathol 35:199–207.
   PubMed Web of Science ®Google Scholar
• Pandurangi AK, Narasimhachari N, Blackard WG, Landa BS. (1989). Relation of serum molindone levels to serum prolactin levels and antipsychotic response. J Clin Psychiatry 50:379–81.
   PubMed Web of Science ®Google Scholar
• Peuskens J, Pani L, Detraux J, De Hert M. (2014). The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 28:421–53.
   PubMed Web of Science ®Google Scholar
• Rosenberg JM, Lau-Cam CA. (1980). Small animal model for evaluating neuroleptic potency. J Pharm Sci 69:74–7.
   PubMed Web of Science ®Google Scholar
• Sikich L, Frazier J, Mcclellan J, et al. (2008). Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) Study. Am J Psychiatry 165:1420–31.
   PubMed Web of Science ®Google Scholar
• Stocks JD, Taneja BK, Baroldi P, Findling RL. (2012). A phase 2a randomized, parallel group, dose-ranging study of molindone in children with attention-deficit/hyperactivity disorder and persistent, serious conduct problems. J Child Adolesc Psychopharmacol 22:102–11.
   PubMed Web of Science ®Google Scholar
• Supernus Pharmaceuticals Inc. (2014). Supernus received FDA fast track designation for SPN-810. Available at: http://ir.supernus.com/releasedetail.cfm?ReleaseID=866208.
   Google Scholar
• US FDA. (2005). Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Available at: http://www.fda.gov/downloads/drugs/guidances/ucm078932.pdf [last accessed 19 Sept 2016].
   Google Scholar
• US FDA. (2009). http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/017111s066lbl.pdf. Moban label - Information obtained for New Drug Application (NDA) 017- 111 through Freedom of Information Act. Available at: http://www.fda.gov/regulatoryinformation/foi/default.htm.
   Google Scholar
• US FDA. (2006). Guidance for Industry: Nonclinical Safety Evaluation of Pediatric Drug Products. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079247.pdf [last accessed 19 Sept 2016].
   Google Scholar
• Zamani Z, Zare S, Sadrkhanlou R, et al. (2015). Chlorpromazine-induced hyperprolactinemia on rat’s uterus. Iran Biomed J 19:226–32.
   PubMedGoogle Scholar
• Zetin M, Cramer M, Garber D, Plon L. (1985). Bioavailability of oral and intramuscular molindone hydrochloride in schizophrenic patients. Clin Therapeutics 7:169–75.
   PubMed Web of Science ®Google Scholar
• Zhang J, Ye L, Wang W, et al. (2015). A 12-week subchronic intramuscular toxicity study of risperidone-loaded microspheres in rats. Hum Exp Toxicol 34:205–23.
   PubMed Web of Science ®Google Scholar